Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helmut Butzkueven

Showing results (171-180 of 390) with videos related to

Pageof 39
Sort By:
The Lancet. Neurology|February 24, 2017
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Laura Balcer, Steven Galetta, et al.
Clinical Epigenetics|February 11, 2023
Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosisMaria Pia Campagna, Alexandre Xavier, Jim Stankovich, et al.
Plos One|May 26, 2011
Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in miceEllen Menkhorst, Jian-Guo Zhang, Natalie A Sims, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
JMIR Research Protocols|October 19, 2021
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)Vicki E Maltby, Rodney A Lea, Mastura Monif, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 1, 2025
Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosisDaniel Merlo, Johnson Ja, Yi Chao Foong, et al.
Scientific Reports|January 3, 2024
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access studyJiwon Oh, Luca Capezzuto, Lito Kriara, et al.
Immunogenetics|January 27, 2007
Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patientsJustin P Rubio, Melanie Bahlo, Jim Stankovich, et al.
Therapeutic Advances in Neurological Disorders|March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsNicholas Riley, Christopher Drudge, Morag Nelson, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Pageof 39

Showing results (171-180 of 390) with videos related to

Sort By:
Pageof 39
The Lancet. Neurology|February 24, 2017
Safety and efficacy of opicinumab in acute optic neuritis (RENEW): a randomised, placebo-controlled, phase 2 trialDiego Cadavid, Laura Balcer, Steven Galetta, et al.
Clinical Epigenetics|February 11, 2023
Parity is associated with long-term differences in DNA methylation at genes related to neural plasticity in multiple sclerosisMaria Pia Campagna, Alexandre Xavier, Jim Stankovich, et al.
Plos One|May 26, 2011
Vaginally administered PEGylated LIF antagonist blocked embryo implantation and eliminated non-target effects on bone in miceEllen Menkhorst, Jian-Guo Zhang, Natalie A Sims, et al.
Multiple Sclerosis and Related Disorders|March 17, 2023
Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosisLana Zhovtis Ryerson, John F Foley, Gilles Defer, et al.
JMIR Research Protocols|October 19, 2021
Efficacy of Cladribine Tablets as a Treatment for People With Multiple Sclerosis: Protocol for the CLOBAS Study (Cladribine, a Multicenter, Long-term Efficacy and Biomarker Australian Study)Vicki E Maltby, Rodney A Lea, Mastura Monif, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 1, 2025
Long-term acceptability of MSReactor digital cognitive monitoring among people living with multiple sclerosisDaniel Merlo, Johnson Ja, Yi Chao Foong, et al.
Scientific Reports|January 3, 2024
Use of smartphone-based remote assessments of multiple sclerosis in Floodlight Open, a global, prospective, open-access studyJiwon Oh, Luca Capezzuto, Lito Kriara, et al.
Immunogenetics|January 27, 2007
Analysis of extended HLA haplotypes in multiple sclerosis and narcolepsy families confirms a predisposing effect for the class I region in Tasmanian MS patientsJustin P Rubio, Melanie Bahlo, Jim Stankovich, et al.
Therapeutic Advances in Neurological Disorders|March 25, 2024
Comparative efficacy of ofatumumab <i>versus</i> oral therapies for relapsing multiple sclerosis patients using propensity score analyses and simulated treatment comparisonsNicholas Riley, Christopher Drudge, Morag Nelson, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|February 15, 2024
Language impairments in seropositive and seronegative autoimmune encephalitisSarah P Griffith, Robb Wesselingh, Fiore D'Aprano, et al.
Pageof 39